Antihypertensive Drugs Market: Rising Global Burden of Hypertension Provides Impetus for Development of New Drugs
Antihypertensive Drugs Market: Introduction
- According to the report, the global antihypertensive drugs market was valued at ~US$ 27.8 Bn in 2018 and is projected to expand at a CAGR of ~2% from 2019 to 2027
- Stroke, also known as cerebrovascular accident, is a medical condition that occurs when the blood supply to the brain is interrupted or blocked. It leads to sudden death of brain cells due to lack of oxygen, which takes place as a result of a rupture of the artery or vein that carries blood to the brain.
- Increase in incidence rate of cardiovascular diseases, owing to changing demographics and rise in prevalence of stroke, diabetes, and hypertension patients is expected to drive the antihypertensive drugs market
- North America held a major share of the global antihypertensive drugs market in 2018, due to the presence of a large population with the history of diabetes, blood pressure related diseases, stroke, rise in mortality associated with the disease, and increase in research funding for antihypertensive drugs in the U.S.
- The antihypertensive drugs market in Asia Pacific is expected to expand at a CAGR of ~3% from 2019 to 2027 due to surge in the number of elderly patients and increase in cardiovascular disorders in patients suffering from hypertension. This, in turn, is likely to drive the demand for antihypertensive drugs in emerging markets such as India and China.
Rise in Prevalence of Stroke to Drive Antihypertensive Drugs Market
- The global geriatric population is projected to increase at a rapid pace over the next few years. Declining fertility and improved longevity are prominent factors for rise in the geriatric population.
- Rise in aging population globally is projected to drive the global antihypertensive drugs market during the forecast period
- For instance, the geriatric population in developing regions is estimated to increase by 154% between 2017 and 2050, exceeding 1.6 billion by 2050. Furthermore, an increase in the number of baby boomers vulnerable to a wide range of age-related diseases has been observed.
- Age is a primary risk factor for hypertension. Prevalence of hypertension is comparatively high in the elderly population; approximately 70% of high blood pressure patients are over the age of 60. Additionally, aging increases blood pressure, as elasticity of the arterial system is reduced. Hence, rise in prevalence of hypertension among the population is projected to drive the antihypertensive drugs market over the next few years.
Request for Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7718
High Demand for Angiotensin Receptor Blockers
- In terms of drug, the global antihypertensive drugs market has been segmented into diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, vasodilators, calcium channel blockers, renin inhibitors, alpha-blockers, and others. The diuretics segment has been sub-segmented into thiazide diuretic, loop diuretics, and potassium-sparing diuretics. The beta-blockers segment has been sub-segmented into beta-1 selective and intrinsic sympathomimetic.
- The angiotensin receptor blockers segment dominated the market in 2018 and this trend is expected to continue during the forecast period
- Rapid adoption and rise in demand for angiotensin receptor blockers have been observed in the recent years, as these are one of the trusted drugs. Additionally, rise in prevalence of hypertension and continually increasing expenses of its treatment influence the prescribing patterns among physicians and compliance to the treatment by the patients. These are expected to drive the segment.
Primary Hypertension a Key Market Driver
- In terms of condition, the global antihypertensive drugs market has been classified into primary hypertension and secondary hypertension
- The primary hypertension segment accounted for major market share in 2018; the trend is expected to continue during the forecast period. Hypertension has become a global health problem in the past decade. In the developed world, salt intake is generally above the recommended quantity among children and a similar trend exists in the developing world.
- Most of the people suffer from primary hypertension. Prevalence of secondary hypertension and the most common etiologies vary with age. Approximately 5% to 10% adults with hypertension have a secondary cause.
Request for Analysis of the COVID19 Impact on Antihypertensive Drugs Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=7718
Greater Effect of Combination Therapy on Hypertension
- Based on medication type, the global antihypertensive drugs market has been categorized into monotherapy, combination therapy, and fixed dose combinations
- By combining two drugs with different mechanisms of action, an antihypertensive effect of two to five times greater than that obtained by monotherapy is possible. In some of the cases, patients who are treated with existing monotherapies fail to achieve target blood pressure. These are the factors which are expected to drive the global antihypertensive drugs market during the forecast period.
Hospital Pharmacies Dominates Antihypertensive Drugs Market
- In terms of distribution channel, the antihypertensive drugs market has been categorized into retail pharmacies, hospital pharmacies, online pharmacies, and others
- The hospital pharmacies segment held a major share of the global antihypertensive drugs market in 2018. Growth of this segment can be attributed to a surge in new cases of stroke and myocardial infarction across the globe and patient preference for treatment in hospitals.
Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=7718
Asia Pacific to Offer Significant Growth Opportunities
- In terms of region, the global antihypertensive drugs market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa
- The antihypertensive drugs market in Asia Pacific is projected to grow at a rapid pace in the near future. India and China are anticipated to be lucrative markets for antihypertensive drugs during the forecast period, owing to high prevalence of cardiac diseases, unhealthy lifestyle choices, such as smoking, poor diet, and high incidence of diabetes and hypertension, which may fuel the risk of a stroke.
- North America is projected to account for a leading share of the global antihypertensive drugs market during the forecast period, owing to increase in incidence rate of cardiovascular diseases, particularly, in the U.S.
- High disposable income of the patient population contributes to the growth of the antihypertensive drugs market in the region. Increase in disposable income drives the uptake of medical and other related services.
- Hypertension is a condition which was recognized in the U.S. much ahead of other regions and antihypertensive drugs were also sold in the country quite early. Furthermore, cases of a number of individuals taking these drugs as a preventive measure have been reported. This, in turn, is expected to drive the demand for antihypertensive drugs in the country
- Favorable funding by government and charitable trusts for stroke research, prevention, and treatment in the U.S. are likely to drive the antihypertensive drugs market in North America
Antihypertensive Drugs Market: Growth Strategies of Key Players
- Key players operating in the global antihypertensive drugs market include Pfizer, Inc., Sanofi S.A., Novartis AG, AstraZeneca plc, and Boehringer Ingelheim GmbH
- These companies are engaging in research & development activities to develop novel products in order to expand product offerings and customer base. For instance, Johnson & Johnson focuses on joint collaboration with leading research institutes, biotech & pharmaceutical companies, and government and non-profit organizations for the development of novel therapeutic products and technologies in different areas. Janssen Biotech, subsidiary of Johnson & Johnson, has more than 150 collaborations across the world in all aspects of healthcare.
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Transparency Market Research
90 State Street,
Albany NY - 12207United States
USA - Canada Toll Free: 866-552-3453